Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dividend dates reminder
-
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- via IBN -- AI Maverick Intel, Inc. (OTCID: BINP) (“AI Maverick” or the “Company”) today announces the full rollout of its next-generation prospecting...
-
Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA...
-
• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a...
-
VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing...
-
Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United...
-
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
-
VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing...
-
ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 ...
-
Rhythm announced pricing of its upsized public offering of 2,058,824 shares of common stock at a price of $85.00 per share.